Literature DB >> 26922542

The preventive role of levosimendan against bleomycin-induced pulmonary fibrosis in rats.

Mehmet Gürbüzel1, Ilyas Sayar2, Murat Cankaya3, Ahmet Gürbüzel4, Levent Demirtas5, Eftal Murat Bakirci6, Ilyas Capoglu5.   

Abstract

BACKGROUND: In this study, the effects of levosimendan used in the treatment of acute congestive heart failure upon pulmonary fibrosis in rats induced with bleomycin (BL) were analyzed.
METHODS: A total of 33 male Sprague-Dawley type rats were categorized into five groups randomly. About 2.5U/kg BL was intratracheally administered to the rats in the BL, BL+L1, BL+L2, and BL+L3 groups, and 0.9% saline was intratracheally administered at the same rate to the control group. 0.3, 1, and 3mg/kg levosimendan was intraperitoneally administered to the BL+L1, BL+L2, and BL+L3 groups, respectively. Blood and tissue samples were taken from the rats euthanized to determine the changes in erythrocyte enzyme activities and to conduct histopathological evaluations after 14 days. With values between 0 and 3, histopathological scoring damage was assessed by the presence of inflammation and fibrosis in a semiquantitative manner.
RESULTS: Compared with those in the C group, glutathione reductase (GR) and Catalase (CAT) enzymes decreased in the BL group; compared with that in the BL group, GR increased in the BL+L1 and BL+L3 groups, 6-phosphogluconate dehydrogenase (6PGD) increased in the BL+L3 group, and CAT increased in the BL+L2 and BL+L3 groups (p<0.05). In the histopathological evaluation, fibrosis occurred in all rats in the BL group, and tissue damage was noticed to be generally less in the BL+L1, BL+L2, and BL+L3 groups (p<0.001).
CONCLUSIONS: The results obtained from biochemical and histopathological evaluations indicate that levosimendan had an anti-fibrotic effect without a dose-dependent response on pulmonary fibrosis.
Copyright © 2015 Institute of Pharmacology, Polish Academy of Sciences. Published by Elsevier Urban & Partner Sp. z o.o. All rights reserved.

Entities:  

Keywords:  Bleomycin; Erythrocyte enzymes; Levosimendan; Pulmonary fibrosis; Rat

Mesh:

Substances:

Year:  2015        PMID: 26922542     DOI: 10.1016/j.pharep.2015.10.001

Source DB:  PubMed          Journal:  Pharmacol Rep        ISSN: 1734-1140            Impact factor:   3.024


  1 in total

1.  Short-term efficacy and safety of levosimendan in patients with chronic systolic heart failure.

Authors:  Xiao-Ran Cui; Xiao-Hong Yang; Rui-Bin Li; Dong Wang; Min Jia; Long Bai; Ji-Dong Zhang
Journal:  Cardiovasc J Afr       Date:  2020-06-12       Impact factor: 1.167

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.